Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Neuro Oncol 2004 6(1):55-62; DOI:10.1215/S1152851703000395
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vernino, S.
Right arrow Articles by Kimmel, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Clinical Investigations

Immunomodulatory treatment trial for paraneoplastic neurological disorders

Steven Vernino1, Brian Patrick O'Neill, Randolph S. Marks, Judith R. O'Fallon and David W. Kimmel

Departments of Neurology (S.V., B.P.O., D.W.K.), Oncology (R.S.M.), and Health Sciences Research (J.R.O.), Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

1 Address correspondence to Steven Vernino, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA (verns{at}mayo.edu).

Abstract

Paraneoplastic neurological disorders are devastating remote effects of malignancy. Despite compelling evidence of an autoimmune pathogenesis, empiric immunomodulatory treatment of these disorders is often ineffective. However, very few systematic studies have been conducted, and the treatment of patients without active malignancy has not been addressed. We conducted a prospective open-label treatment study of plasma exchange plus conventional cancer chemotherapy (10 patients) or plasma exchange plus continuous oral cyclophosphamide (10 patients). All patients had progressive symptoms and at least moderate disability at enrollment (mean Rankin score, 3.4). Patients who had experienced symptoms for more than 12 months were excluded (mean duration of symptoms at enrollment, 3.6 months). The primary outcome measure was change in quantitative disability measures (Rankin and Barthel scores) after 6 months of treatment; a positive response was defined as stability or improvement in disability. Overall, 50% of patients had a positive response at 6 months (6 patients had improved by at least 1 Rankin grade). Patients with good outcome tended to be those with less disability at time of enrollment. Hematologic toxicity was common among those receiving cyclophosphamide. Aggressive immunosuppression early in the clinical course should be considered in patients who have paraneoplastic neurological disorders, even when there is no evidence of active malignancy.

References

Albert, M.L., Darnell, J.C., Bender, A., Francisco, L.M., Bhardwaj, N., and Darnell, R.B. (1998) Tumor-specific killer cells in paraneoplastic cerebel lar degeneration. Nat. Med. 4,1321 -1324.[CrossRef][Web of Science][Medline]

Albert, M.L., Austin, L.M., and Darnell, R.B. (2000) Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47,9 -17.[CrossRef][Web of Science][Medline]

Bataller, L., Graus, F., Saiz, A., Vilchez, J.J., and Spanish Opsoclonus-Myoclonus Study G (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124,437 -443.[Abstract/Free Full Text]

Batchelor, T.T., Platten, M., and Hochberg, F.H. (1998) Immunoadsorption therapy for paraneoplastic syndromes. J. Neurooncol. 40,131 -136.[CrossRef][Medline]

Batson, O.A., Fantle, D.M., and Stewart, J.A. (1992) Paraneoplastic encephalomyelitis. Dramatic response to chemotherapy alone. Cancer 69,1291 -1293.[Web of Science][Medline]

Blaes, F., Strittmatter, M., Merkelbach, S., Jost, V., Klotz, M., Schimrigk, K., and Hamann, G.F. (1999) Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J. Neurol. 246,299 -303.[CrossRef][Web of Science][Medline]

Bruyland, M., Van Belle, S., Schallier, D., Ebinger, G., and Martin, J.J. (1984) Good response of a paraneoplastic neuromyopathy to cyclophos phamide. Cancer Treat. Rep. 68,787 -789.[Web of Science][Medline]

Cocconi, G., Ceci, G., Juvarra, G., Minopoli, M.R., Cocchi, T., Fiaccadori, F., Lechi, A., and Boni, P. (1985) Successful treatment of subacute cerebel lar degeneration in ovarian carcinoma with plasmapheresis. A case report. Cancer 56,2318 -2320.[CrossRef][Web of Science][Medline]

Counsell, C.E., McLeod, M., and Grant, R. (1994) Reversal of subacute para neoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 44,1184 -1185.[Free Full Text]

Dalmau, J.O., and Posner, J.B. (1997) Paraneoplastic syndromes affecting the nervous system. Semin. Oncol. 24,318 -328.[Web of Science][Medline]

David, Y.B., Warner, E., Levitan, M., Sutton, D.M., Malkin, M.G., and Dalmau, J.O. (1996) Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 78,2153 -2156.[CrossRef][Web of Science][Medline]

Dropcho, E.J. (1995) Autoimmune central nervous system paraneoplastic disorders: Mechanisms, diagnosis, and therapeutic options. Ann. Neurol. 37,S102 -S113.

Faris, M., Abraham, J., and Barrett-Lee, P. (1998) A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: Response to CMF chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 10,202 -203.

Glantz, M.J., Biran, H., Myers, M.E., Gockerman, J.P., and Friedberg, M.H. (1994) The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. Cancer 73,168 -175.[CrossRef][Web of Science][Medline]

Graus, F., Dalmou, J., Rene, R., Tora, M., Malats, N., Verschuuren, J.J., Car denal, F., Vinolas, N., Garcia del Muro, J., Vadell, C., Mason, W.P., Rosell, R., Posner, J.B., and Real, F.X. (1997) Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J. Clin. Oncol. 15,2866 -2872.[Abstract]

Graus, F., Keime-Guibert, F., Rene, R., Benyahia, B., Ribalta, T., Ascaso, C., Escaramis, G., and Delattre, J.Y. (2001) Anti-Hu-associated paraneoplas tic encephalomyelitis: Analysis of 200 patients. Brain 124,1138 -1148.[Abstract/Free Full Text]

Graus, F., Vega, F., Delattre, J.Y., Bonaventura, I., Rene, R., Arbaiza, D., and Tolosa, E. (1992) Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 42,536 -540.[Abstract/Free Full Text]

Grisold, W., Drlicek, M., Liszka-Setinek, U., and Wondrusch, E. (1995) Anti-tumour therapy in paraneoplastic neurological disease. Clin. Neurol. Neurosurg. 97,106 -111.[CrossRef][Web of Science][Medline]

Guy, J., and Aptsiauri, N. (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: Report of 3 cases. Arch. Ophthalmol. 117,471 -477.[Abstract/Free Full Text]

Jaeckle, K.A. (1996) Paraneoplastic nervous system syndromes. Curr. Opin. Oncol. 8, 204-208.[Medline]

Keime-Guibert, F., Graus, F., Fleury, A., Rene, R., Honnorat, J., Broet, P., and Delattre, J.Y. (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J. Neurol. Neurosurg. Psychiatr. 68,479 -482.[Abstract/Free Full Text]

Lennon, V.A. (1994) Paraneoplastic autoantibodies: The case for a descrip tive generic nomenclature. Neurology 44,2236 -2240.[Free Full Text]

Mahoney, F., and Barthel, D. (1965) Functional evaluation: The Barthel index. MD State Med. J. 14, 61-65.[Medline]

Moll, J.W., Henzen-Logmans, S.C., Van der Meche, F.G., and Vecht, C.H (1993) Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration [comment]. J. Neurol. Neurosurg. Psychiatr. 56,112 .

Mowzoon, N., and Bradley, W.G. (2000) Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: A case report. J. Neurol. Sci. 178, 63-65.[CrossRef][Web of Science][Medline]

NCI. National Cancer Institute (1999) Common Toxicity Criteria version 2.0. Available at https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ctc000w$.startup.

Oh, S.J., Slaughter, R., and Harrell, L. (1991) Paraneoplastic vasculitic neuropathy: A treatable neuropathy. Muscle Nerve 14,152 -156.[CrossRef][Web of Science][Medline]

Oh, S.J., Dropcho, E.J., and Claussen, G.C. (1997) Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: Report of two cases and review of literature. Muscle Nerve 20,1576 -1582.[CrossRef][Web of Science][Medline]

Rankin, J. (1957) Cerbral vascular accidents in patients over the age of 60: II. Prognosis. Scott. Med. J. 2,200 -215.[Medline]

Rickman, O.B., Parisi, J.E., Yu, Z., Lennon, V.A., and Vernino, S. (2000) Ful minant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin. Proc. 75,1321 -1326.[Abstract]

Rojas, I., Graus, F., Keime-Guibert, F., Rene, R., Delattre, J.Y., Ramon, J., Dalmau, J., Posner, J.B. (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55,713 -715.[Abstract/Free Full Text]

Schmierer, K., Valdueza, J.M., Bender, A., DeCamilli, P., David, C., Solimena, M., and Zschenderlein, R. (1998) Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology 51,250 -252.[Abstract/Free Full Text]

Sillevis Smitt, P., Grefkens, J., de Leeuw, B., van den Bent, M., van Putten, W., Hooijkaas, H., and Vecht, C. (2002) Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J. Neurol. 249,745 -753.[CrossRef][Web of Science][Medline]

Stark, E., Wurster, U., Patzold, U., Sailer, M., and Haas, J. (1995) Immunological and clinical response to immunosuppressive treatment in parane oplastic cerebellar degeneration. Arch. Neurol. 52,814 -818.[Abstract/Free Full Text]

Uchuya, M., Graus, F., Vega, F., Rene, R., and Delattre, J.Y. (1996) Intravenous immunoglobulin treatment in paraneoplastic neurological syn dromes with antineuronal autoantibodies. J. Neurol. Neurosurg. Psychiatr. 60,388 -392.[Abstract/Free Full Text]

Weissman, D.E., and Gottschall, J.L. (1989) Complete remission of paraneoplastic sensorimotor neuropathy: A case associated with small-cell lung cancer responsive to chemotherapy, plasma exchange, and radiotherapy. J. Clin. Apheresis 5, 3-6.[Medline]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
The OncologistHome page
J. W. de Beukelaar and P. A. S. Smitt
Managing paraneoplastic neurological disorders.
Oncologist, March 1, 2006; 11(3): 292 - 305.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vernino, S.
Right arrow Articles by Kimmel, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2004 by Society for Neuro-Oncology